title: Variations in plasma free radicals in patients with venous hypertension with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a clinical, prospective, placebo-controlled, randomized trial.
abstract: The aim of this study was to demonstrate whether HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides), was effective in improving levels of plasma free radicals (PFRs) in patients with chronic venous insufficiency (CVI) and venous microangiopathy. Patients were randomized into the treatment group, which received oral HR (1g sachets, twice daily, for 4 weeks), and a placebo group, which received comparable placebo. Below-knee Sigvaris stockings were used during the study. PFRs were measured with the D-Rom test at the finger and at a vein of the leg in an area of CVI. The mean age of included subjects was 46 years (SD 11) in the treatment group (20 patients; 6 females) and 46.4 (SD 8) in the placebo group (20 patients; 7 females). There were no differences between placebo and treatment groups at inclusion in age and sex distribution and in parameters indicating venous hypertension. The decrease of PFRs levels in the treatment group was significant, both at the finger and in the distal blood taken in areas of CVI. There there were no significant changes in the control group. In areas of venous hypertension, PFRs values were on average higher than at the finger (systemic) level (P < 0.05). In parallel with the progressive decrease in PFRs associated with treatment, the analogue score was significantly decreased at 2 (P < 0.05) and 4 weeks (P < 0.02) in the HR group. No changes were observed in the placebo group. No adverse effects were observed. In conclusion, HR treatment is effective in decreasing both the systemic and local values of PFRs and therefore may have a positive effect on the evolution of CVI.
authors.affiliation: Irvine2 Vasc Lab and Physiology, Department of Biomedical Sciences, Chieti University, San Valentino Vascular Screening Project, Italy.
authors.forename: M R
authors.initials: MR
authors.lastname: Cesarone
authors.forename: L
authors.initials: L
authors.lastname: Incandela
authors.forename: M T
authors.initials: MT
authors.lastname: DeSanctis
authors.forename: G
authors.initials: G
authors.lastname: Belcaro
authors.forename: M
authors.initials: M
authors.lastname: Dugall
authors.forename: G
authors.initials: G
authors.lastname: Acerbi
mesh_terms: D000328:Adult; D005260:Female; D005609:Free Radicals / Q000097:blood*; D006801:Humans; D006896:Hydroxyethylrutoside / Q000031:analogs & derivatives* / Q000494:pharmacology*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011446:Prospective Studies; D012883:Skin Ulcer; D016896:Treatment Outcome; D014648:Varicose Veins / Q000150:complications / Q000188:drug therapy; D014652:Vascular Diseases / Q000188:drug therapy*; D014689:Venous Insufficiency / Q000188:drug therapy*
chemical_list: D005609:Free Radicals; D006896:Hydroxyethylrutoside; D010919:Placebos; C005865:troxerutin